Dr. Martini has more than 25 years of experience in drug discovery, working on molecular mechanisms underlying monogenic and multigenic metabolic and fibrotic disorders. Dr. Martini previously served as Chief Scientific Officer International Therapeutics Research Centers and was the Founder of Moderna Rare Diseases at Moderna, Inc., where his laboratory focused on identifying novel therapies and applying translational approaches for drug development in Rare Diseases and Hematology disorders.
Previously at Shire Pharmaceutical, Dr. Martini’s focus was on fibrotic diseases of muscle, kidney, skin, lung, bone marrow and metabolic liver diseases with particular emphasis on different therapeutic modalities for pathway modulation. Earlier in his career, at EMD-Serono, he focused on identifying key compounds for breast cancer treatment and understanding the complexity of breast tumor tissues and related markers. Dr. Martini is the author of more than 50 publications in high peer-reviewed journals and several articles on scientific magazines spanning from oncology research to rare genetic disorder.
Born in Milano, Italy, Dr. Martini studied at the University of Milano in Italy and graduated with a Ph.D. in Molecular Endocrinology, focusing on hormone-dependent cancers such as breast and prostate cancers. He serves as a member of the Scientific Advisory Board of Certa Therapeutics (Melbourne, AUS), Gingko Bioworks (Boston, MA), and the Institute of Life Changing Medicines (USA), a non-profit organization focusing on CN1 (Crigler-Najjar disease type 1).
Back to Team